University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Published

April 29, 2022

University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery…

MORERelated News
Ros Deegan: Always up for a new challenge: How Ros carved out a path to lead her own company
Always up for a new challenge, Ros describes the many twists and turns her career has taken over the years....
Lab crunch: British science has nowhere to go
OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm...
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...